Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.
CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks